MRRS adds "Frontier Pharma: Hematological Cancers – Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow, and include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating that lymphomas are more prevalent than leukemia or myeloma. Excluding acute lymphocytic leukemia and Hodgkin’s lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent.

The report assesses first-in-class innovation in the hematological cancer pipeline, highlighting key trends in first-in-class product distribution. Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry, with 463 first-in-class products, representing 45.3% of the pipeline with a disclosed molecular target.

The first-in-class targets in the pipeline are numerous and varied in nature. Cancer immunotherapies are the most common, with a total of 128 across all stages of development, followed by the signal transduction group of targets. The most commercially successful targeted drugs in the market fall into these two categories, including Rituxan (a cancer immunotherapy) and Gleevec (a signal transducer). The other target families have much fewer first-in-class products, reflecting the strong interest in cancer immunotherapies and targets implicated in signal transduction.

Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 Significant Unmet Needs Persist in Hematological Cancer Market 5
2.2 Large Hematological Cancer Pipeline Displays Strong Degree of Innovation 5
2.3 Leuekmia Displays Most Pipeline Activity among Hematological Cancer Indications 5
3 The Case for Innovation in Hematological Cancers 6
3.1 Growing Number of Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 9
4 Clinical and Commercial Landscape 10
4.1 Disease Overview 10
4.2 Epidemiology 10
4.2.1 Leukemia 10
4.2.2 Lymphoma 11
4.2.3 Myeloma 11
4.3 Pathophysiology 12
4.3.1 Leukemia 12
4.3.2 Lymphoma 13
4.3.3 Myeloma 15
4.4 Symptoms 16
4.5 Diagnosis 16
4.5.1 Leukemia 16
4.5.2 Lymphoma 16
4.5.3 Myeloma 17
4.6 Prognosis and Survival 17
4.6.1 Survival 19
4.7 Treatment 19
4.7.1 Surgery and Radiation Therapy 20
4.7.2 Stem-Cell Transplantation 20
4.7.3 Pharmacological 21
4.8 Overview of Marketed Products 22
4.8.1 Conclusion 24
4.8.2 Unmet Need 24
5 Assessment of Pipeline Product Innovation 25......

List of Tables and Figures 
Table 1: Hematological Cancers Therapeutics Market, Global, Epidemiology of Hematological Disease Severity, 2016 10
Table 2: Hematological Cancers Therapeutics Market, Global, Lymphoma, Prognostic Factors, 2016 18
Table 3: Hematological Cancers Therapeutics Market, Global, Prognostic Factors, 2016 19
Table 4: Hematological Cancer Therapeutics Market, Global, Commonly Used Chemo-Regimens 21
Table 5: Hematological Cancers Therapeutics Market, Global, Data for IL-7R Alpha as a Therapeutic Target, 2016 47
Table 6: Hematological Cancers Therapeutics Market, Global, Data for Notch 2 and Notch 3 as a Therapeutic Target, 2016 48
Table 7: Hematological Cancers Therapeutics Market, Global, Focal Adhesion Kinase as a Therapeutic Target, 2016 49
Table 8: Hematological Cancers Therapeutics Market, Global, MALT1 as a Therapeutic Target, 2016 Table 9: Hematological Cancers Therapeutics Market, Global, IL1RAP as a Therapeutic Target, 2016 Table 10: Hematological Cancers Therapeutics Market, Global, HLA-DR as a Therapeutic Target, 2016 51.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/frontier-pharma-hematological-cancers-highly-innovative-pipeline-continues-trend-towards-targeted-patient-specific-therapies

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/